Upcoming Earnings: Q3 '26
Estimated EPS
-$0.20
Estimated Rev
$0.25M
• Reported GAAP EPS of $0.03 up 111.54% YoY • Reported revenue of $18.67M up 1031.52% YoY
Bullish Takeaway
AC Immune significantly grew revenue through strategic pharmaceutical collaborations while advancing its clinical-stage pipeline and securing external grant funding to support key neurodegenerative disease research programs for the company.
Bearish Takeaway
AC Immune faces ongoing net losses and a reduction in total cash resources alongside a leadership transition, as the company operates with an interim Chief Executive Officer following management changes.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.20 | -- | -- | N/A |
Q2 '26 | -$0.10 | -- | -- | N/A |
Q1 '26 | -$0.19 | -$0.19 | 3.87% | BEAT |
Q4 '25 | -$0.22 | -- | -- | N/A |
Q3 '25 | -$0.23 | -$0.16 | 28.13% | BEAT |